Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. [electronic resource]
Producer: 20130402Description: 1841-9 p. digitalISSN:- 1875-8312
- Adenosine A2 Receptor Antagonists -- adverse effects
- Aged
- Asthma -- complications
- Atrioventricular Block -- chemically induced
- Bronchoconstriction -- drug effects
- Chi-Square Distribution
- Female
- Heart Diseases -- complications
- Hemodynamics -- drug effects
- Humans
- Male
- Middle Aged
- Myocardial Perfusion Imaging -- methods
- Organophosphorus Compounds
- Organotechnetium Compounds
- Predictive Value of Tests
- Pulmonary Disease, Chronic Obstructive -- complications
- Purines -- adverse effects
- Pyrazoles -- adverse effects
- Radiopharmaceuticals
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Tachycardia, Supraventricular -- chemically induced
- Tomography, Emission-Computed, Single-Photon
- Vasodilator Agents -- adverse effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.